Skip to main content

Daniel Kelly Benjamin, MD, PhD

Kiser-Arena Distinguished Professor of Pediatrics
Professor of Pediatrics
Member in the Duke Clinical Research Institute
Campus mail: 7044 Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27710
Phone: (919) 668-7081

Dr. Danny Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network. The Network is responsible for designing and leading clinical trials of off-patent medicines in children of all ages across all therapeutic areas. The team has established, or is actively studying, the correct dosing and safety of more than 50 of the most commonly used medicines in children. Each of these trials is conducted under an investigational new drug (IND) application with guidance from the Food and Drug Administration for labeling.

Signature programs of the Network include clinical trials in premature, term infants and most recently, obese children. Over the past 10 years, Dr. Benjamin’s group has enrolled more premature infants, at more sites, in more clinical trials of off-patent anti-infectives under an IND than all other academic medical centers, pharmaceutical companies, and government agencies in the world, combined.

Dr. Benjamin is recognized by the National Institutes of Health as a premiere mentor and educator. His research program serves as a platform to train students and early career investigators. Dr. Benjamin’s group has a clinical research summer program for high school and college students targeting under-represented minority students, and he is the primary mentor for medical students, residents, subspecialty fellows (including two T32 programs sponsored by NIH for which he is PI), and multiple junior faculty.

Dr. Benjamin has published over 250 works with up to 7000 citations. 

Education and Training

  • Fellow, Pediatric Infectious Diseases, Pediatrics, Duke University, 1998 - 2001
  • Resident, Pediatrics, Children's Hospital, 1995 - 1998
  • Ph.D., University of North Carolina at Chapel Hill, 2003
  • M.P.H., University of North Carolina at Chapel Hill, 2001
  • M.D., University of Virginia, 1995

Selected Grants and Awards

Publications

Rowe, Stevie, David Siegel, Daniel K. Benjamin, and Daniel K. Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee. “Gaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Emergency Care Medications.” Clin Ther 37, no. 9 (September 1, 2015): 1924–32. https://doi.org/10.1016/j.clinthera.2015.08.006.

Full Text

Bergin, Stephen P., Joshua T. Thaden, Jessica E. Ericson, Heather Cross, Julia Messina, Reese H. Clark, Vance G. Fowler, et al. “Neonatal Escherichia coli Bloodstream Infections: Clinical Outcomes and Impact of Initial Antibiotic Therapy.” Pediatr Infect Dis J 34, no. 9 (September 2015): 933–36. https://doi.org/10.1097/INF.0000000000000769.

Full Text

Ericson, Jessica E., Christopher Arnold, Jomani Cheeseman, Jordan Cho, Sarah Kaneko, Ele’na Wilson, Reese H. Clark, et al. “Use and Safety of Erythromycin and Metoclopramide in Hospitalized Infants.” J Pediatr Gastroenterol Nutr 61, no. 3 (September 2015): 334–39. https://doi.org/10.1097/MPG.0000000000000792.

Full Text

Harskamp-van Ginkel, Margreet W., Kevin D. Hill, Kristian C. Becker, Daniela Testoni, Michael Cohen-Wolkowiez, Daniel Gonzalez, Jeffrey S. Barrett, et al. “Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review.” Jama Pediatr 169, no. 7 (July 2015): 678–85. https://doi.org/10.1001/jamapediatrics.2015.132.

Full Text

Watt, Kevin M., Daniel Gonzalez, Daniel K. Benjamin, Kim L. R. Brouwer, Kelly C. Wade, Edmund Capparelli, Jeffrey Barrett, and Michael Cohen-Wolkowiez. “Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.” Antimicrob Agents Chemother 59, no. 7 (July 2015): 3935–43. https://doi.org/10.1128/AAC.00102-15.

Full Text

Botero-Calderon, Lorena, Daniel K. Benjamin, and Michael Cohen-Wolkowiez. “Advances in the treatment of invasive neonatal candidiasis.” Expert Opin Pharmacother 16, no. 7 (May 2015): 1035–48. https://doi.org/10.1517/14656566.2015.1031108.

Full Text

Camelo Castillo, Wendy, Kim Boggess, Til Stürmer, M Alan Brookhart, Daniel K. Benjamin, and Michele Jonsson Funk. “Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes.” Jama Pediatr 169, no. 5 (May 2015): 452–58. https://doi.org/10.1001/jamapediatrics.2015.74.

Full Text

Arnold, Christopher J., Jessica Ericson, Jordan Kohman, Kaitlyn L. Corey, Morgan Oh, Janet Onabanjo, Christoph P. Hornik, et al. “Rifampin use and safety in hospitalized infants.” Am J Perinatol 32, no. 6 (May 2015): 565–70. https://doi.org/10.1055/s-0034-1543955.

Full Text

Johnson, Jason N., Christoph P. Hornik, Jennifer S. Li, Daniel K. Benjamin, Terry Yoshizumi, Robert E. Reiman, Donald P. Frush, and Kevin D. Hill. “Response to letters regarding article, "Cumulative radiation exposure and cancer risk estimation in children with heart disease".” Circulation 131, no. 16 (April 21, 2015): e419–20. https://doi.org/10.1161/CIRCULATIONAHA.114.013266.

Full Text

Ericson, Jessica E., Joshua Thaden, Heather R. Cross, Reese H. Clark, Vance G. Fowler, Daniel K. Benjamin, Michael Cohen-Wolkowiez, Christoph P. Hornik, P Brian Smith, and P Brian Antibacterial Resistance Leadership Group. “No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants.” Pediatr Infect Dis J 34, no. 4 (April 2015): 371–75. https://doi.org/10.1097/INF.0000000000000573.

Full Text

Pages